- Home
- TNXP vs SST Comparison
TNXP vs SST Comparison
Compare TNXP & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- SST
- Stock Information
- Founded
- TNXP 2007
- SST 2013
- Country
- TNXP United States
- SST United States
- Employees
- TNXP N/A
- SST N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- SST Diversified Commercial Services
- Sector
- TNXP Health Care
- SST Consumer Discretionary
- Exchange
- TNXP Nasdaq
- SST Nasdaq
- Market Cap
- TNXP 71.6M
- SST 67.8M
- IPO Year
- TNXP N/A
- SST N/A
- Fundamental
- Price
- TNXP $0.38
- SST $0.68
- Analyst Decision
- TNXP Strong Buy
- SST Hold
- Analyst Count
- TNXP 2
- SST 1
- Target Price
- TNXP $53.50
- SST $2.00
- AVG Volume (30 Days)
- TNXP 102.7M
- SST 1.2M
- Earning Date
- TNXP 11-12-2024
- SST 03-17-2025
- Dividend Yield
- TNXP N/A
- SST N/A
- EPS Growth
- TNXP N/A
- SST N/A
- EPS
- TNXP N/A
- SST N/A
- Revenue
- TNXP $11,291,000.00
- SST $364,450,000.00
- Revenue This Year
- TNXP $64.71
- SST N/A
- Revenue Next Year
- TNXP $24.49
- SST $2.59
- P/E Ratio
- TNXP N/A
- SST N/A
- Revenue Growth
- TNXP 183.05
- SST N/A
- 52 Week Low
- TNXP $0.12
- SST $0.60
- 52 Week High
- TNXP $12.48
- SST $2.73
- Technical
- Relative Strength Index (RSI)
- TNXP 55.72
- SST 41.23
- Support Level
- TNXP $0.37
- SST $0.63
- Resistance Level
- TNXP $0.58
- SST $0.74
- Average True Range (ATR)
- TNXP 0.07
- SST 0.12
- MACD
- TNXP 0.01
- SST -0.00
- Stochastic Oscillator
- TNXP 43.06
- SST 16.69
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.